These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12010622)

  • 41. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P; Vakil N; Monyak JT; Silberg DG
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
    Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
    Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erosive Esophagitis Portends a Benign Clinical Course in the Majority of Patients.
    Bi D; Katzka DA; Lavey CJ; Geno DM; Ravi K
    Dig Dis Sci; 2020 Nov; 65(11):3244-3252. PubMed ID: 31907769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of surgical patients with gastroesophageal reflux disease and Barrett's esophagus].
    Zsolt S; Paszt A; Géczi T; Abrahám S; Tóth I; Horváth Z; Pieler J; Tajti J; Varga A; Tiszlavicz L; Németh I; Izbéki F; Rosztóczy A; Wittmann T; Lázár G
    Magy Seb; 2014 Oct; 67(5):287-96. PubMed ID: 25327403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastroesophageal reflux disease (GERD): current agents and future perspective.
    Lanas A; Santolaria S
    Curr Pharm Des; 2001 Jan; 7(1):1-18. PubMed ID: 11172698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Primary care for GEDR].
    Takeda H
    Nihon Rinsho; 2004 Aug; 62(8):1499-503. PubMed ID: 15344540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical treatments of GERD: the old and new.
    Vela MF
    Gastroenterol Clin North Am; 2014 Mar; 43(1):121-33. PubMed ID: 24503363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
    Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
    Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review article: treatment of mild and severe cases of GERD.
    Tytgat GN
    Aliment Pharmacol Ther; 2002 Jul; 16 Suppl 4():73-8. PubMed ID: 12047264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Critical issues in the management of gastroesophageal reflux disease.
    Freston JW; Malagelada JR; Petersen H; McCloy RF
    Eur J Gastroenterol Hepatol; 1995 Jun; 7(6):577-86. PubMed ID: 7552644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of medical therapy and antireflux surgery to prevent Barrett's metaplasia in patients with gastroesophageal reflux disease.
    Wetscher GJ; Gadenstaetter M; Klingler PJ; Weiss H; Obrist P; Wykypiel H; Klaus A; Profanter C
    Ann Surg; 2001 Nov; 234(5):627-32. PubMed ID: 11685025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.